Clinical trials: Ribavirin
Chronic Hepatitis C
Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.
The purpose of the study was to determine safety and efficacy of 48 weeks treatment with Thymosin alpha 1 (Talpha1) in combination with pegylated interferon (PEGIFN) alpha2a and ribavirin (RBV) in adult patients with chronic…
- Trial name
- NCT01178996
- Testing
- Thymosin alpha 1, Ribavirin, PEGinterferon alfa2a
- Where
- 9 sites in France, Germany and 3 more
- Volunteers
- 552 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Hepatitis C
Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in treatment-naïve patients with (Genotype 1) hepatitis C.
- Trial name
- NCT00780416
- Testing
- MP-424, Ribavirin, Peginterferon Alfa-2b
- Where
- Japan
- Volunteers
- 189 people
- Sponsor
- Tanabe Pharma Corporation
Hepatitis C
A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)
The PROVE3 trial is a partially double blinded, randomized, Phase 2 research study of an investigational drug, Telaprevir (VX-950) or Placebo, with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a, Pegasys®), and Ribavirin (RBV…
- Trial name
- NCT00420784
- Testing
- Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a
- Where
- 53 sites in United States, Canada and 3 more
- Volunteers
- 465 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C, Chronic
This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C
The objective of this trial is to investigate tolerability, safety, pharmacokinetics and antiviral activity of BI 207127 NA in combination with BI 201335 NA and ribavirin for 8 weeks in Japanese treatment-naive patients with…
- Trial name
- NCT01528735
- Testing
- BI 207127 NA, peginterferon, Ribavirin
- Where
- 5 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Boehringer Ingelheim
Chronic Hepatitis C
Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)
The study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO) and work productivity data of the interferon-free ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir +/- dasabuvir) +/- Ribavirin…
- Trial name
- REAL (NCT02582658)
- Volunteers
- 173 people
- Sponsor
- AbbVie
Hepatitis C Virus Infection
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
The purpose of this study was to evaluate the efficacy and safety of co-administration of glecaprevir (ABT-493)/pibrentasvir (ABT 530) plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 …
- Trial name
- MAGELLAN-3 (NCT02939989)
- Testing
- Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 33 people
- Sponsor
- AbbVie
Adenovirus
Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia
This is a randomized, controlled, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetic (PK), and adenovirus (AdV) antiviral activity of multiple ascending doses of IV brincidofovir (BCV).
- Trial name
- NCT03532035
- Testing
- Brincidofovir, Standard of Care
- Where
- 8 sites in United States, Italy and 1 more
- Sponsor
- Jazz Pharmaceuticals
Chronic Hepatitis C Infection
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection
The purpose of this study is to evaluate the safety and antiviral activity of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir) and ABT-333 (also known as…
- Trial name
- PEARL-III (NCT01767116)
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin
- Volunteers
- 419 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hepatitis C Virus
TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin
The purpose of this study is to determine in genotype 1 Hepatitis C Virus (HCV)-infected participants, the safety, tolerability, pharmacokinetics (how the drug is absorbed in the body, how it is distributed within the body and…
- Trial name
- NCT01391117
- Testing
- TMC649128., TMC649128
- Where
- 3 sites in Netherlands, Poland
- Volunteers
- 14 people
- Sponsor
- Tibotec BVBA
Hepatitis C, Chronic, Hepatitis C
Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)
The objective of the study is to evaluate the costs associated with peginterferon alfa-2b (PegIntron) plus ribavirin (Rebetol) treatment for chronic hepatitis C in the Czech Republic.
- Trial name
- NCT00723632
- Testing
- peginterferon alfa-2b, ribavirin
- Volunteers
- 901 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C
This 3-arm study assessed the safety and efficacy of combination treatment with peginterferon alfa-2a + ribavirin in participants with chronic hepatitis C.
- Trial name
- NCT00800748
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 35 sites in Czechia, Slovakia
- Volunteers
- 372 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure
This prospective, national, multicenter, observational study will evaluate in routine clinical practice the efficacy and safety of re-treatment with Pegasys (peginterferon alfa-2a) plus ribavirin or regimens containing…
- Trial name
- NCT01798576
- Testing
- Pegylated Interferon alfa-2a, Ribavirin
- Where
- Romania
- Volunteers
- 282 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)
This open-label, multicenter, phase IV study will evaluate the relationship between the drop in hemoglobin levels and sustained virological response in patients with chronic hepatitis C genotype 1 treated with Copegus (ribavirin)…
- Trial name
- NCT01585324
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
- Where
- Czechia
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
This study will evaluate the safety, tolerability, and antiviral efficacy of GS-7977 with ribavirin (RBV) in participants with genotype 2 or 3 hepatitis C virus (HCV) infection.
- Trial name
- NCT01682720
- Testing
- SOF, RBV
- Where
- 77 sites in Austria, Estonia and 8 more
- Volunteers
- 421 people
- Sponsor
- Gilead Sciences
Hepatitis, Hepatitis C
Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C
The purpose of the study is to demonstrate the noninferiority of Algeron 1.5 and 2.0 μg/kg/week in combination with ribavirin compared to PegIntron in combination with ribavirin in the treatment of chronic hepatitis C, and to…
- Trial name
- NCT01740089
- Testing
- Algeron, PegIntron, Ribavirin
- Where
- Russia
- Volunteers
- 150 people
- Sponsor
- Biocad
HCV Infection
Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
The purpose of this study is to assess the safety, tolerability and effectiveness of ANA598 when administered with pegylated interferon and ribavirin (Standard of Care [SOC]) compared to placebo + SOC.
- Trial name
- NCT00978497
- Testing
- ANA598, Peginterferon, Ribavirin
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 97 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype
The purpose of this study is to evaluate if a 12-week total regimen of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) (T12/PR12) is safe and effective in subjects who have the…
- Trial name
- CONCISE (NCT01459913)
- Testing
- Telaprevir, Pegylated Interferon Alfa-2a, Ribavirin
- Where
- 83 sites in United States, Austria and 4 more
- Volunteers
- 239 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C, Chronic
An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)
This observational study will assess factors leading to dose reductions/treatment discontinuations and the effect on sustained virological response in patients with chronic hepatitis C receiving a long-acting interferon (e.g.
- Trial name
- NCT01344889
- Where
- 260 sites in Albania, Algeria and 23 more
- Volunteers
- 4,459 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Virus
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)
The purpose of this study in HCV genotype 4-infected participants with compensated cirrhosis is to assess the safety and to compare the percentage of participants achieving a 12-week sustained virologic response (SVR12), [HCV…
- Trial name
- AGATE-1 (NCT02265237)
- Testing
- ombitasvir/paritaprevir/ritonavir, ribavirin
- Volunteers
- 184 people
- Sponsor
- AbbVie
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)
The interferon-free combination regimen of paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- LIFE-C (NCT02615145)
- Volunteers
- 472 people
- Sponsor
- AbbVie